Nisa Investment Advisors
ACTU

Nisa Investment Advisors’s Actuate Therapeutics ACTU Stock Holding History

Nisa Investment Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511 Buy
334
+247
+284% +$572 ﹤0.01% 2940
2026
Q1 		$238 Buy
+87
New +$360 ﹤0.01% 2973

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Nisa Investment Advisors's ACTU Position: Q2 2026 in Review

Nisa Investment Advisors increased its Actuate Therapeutics (ACTU) stake by 284% in Q2 2026, buying an estimated $572 and bringing the position to 334 shares worth $511. The position accounts for ﹤0.01% of the portfolio, ranked #2940.

Nisa Investment Advisors first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Nisa Investment Advisors held 334 shares of Actuate Therapeutics worth $511 as of Q2 2026.
  • Nisa Investment Advisors bought 247 Actuate Therapeutics shares in Q2 2026, an estimated $572.
  • Actuate Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2940 holding.
  • Nisa Investment Advisors first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.